FDA: Product quality issues fuel rise in drug shortages

"A very large number of quality product issues" is what Valerie Jensen, associate director for FDA's drug shortage program (CDER), cites as the major cause of the 178 shortages counted by the regulator in 2010. To be precise, product quality played a role in 54% of shortages. Some of the issues were sterility or impurities; others were production delays or capacity problems. "In 2011, we're seeing the same trend." Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.